PATENT CLAIM ANALYSIS

Application Number: 15944483
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["514", "04400A"]

Abstract:
Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.

Claim (Index 2):
The molecule of  claim 1 , comprising the nucleic acid inhibitor of Cdc25C coupled to the nucleic acid inhibitor of PP2Ac\u03b1 by a bivalent linker.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.78261
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14761641', '15682062', '14648306', '14902719', '15328235']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6964526572037515
- 35 USC 102 Novelty (BERT): 0.5911229384393187
- Combined Prediction Score: 0.6859196853273083
- Mean Citation Score: 282.474854
- Max Citation Score: 512.15216
- Similarity Product: 412.2200044156265

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test